Skip to content

Feasibility and Outcomes of a Digital Health Support for the Schizophrenia Spectrum

Testing the Feasibility and Outcomes of a Digital Health Support for Individuals With Schizophrenia Spectrum Mental Illnesses

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03649815
Enrollment
38
Registered
2018-08-28
Start date
2017-04-18
Completion date
2018-05-08
Last updated
2020-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia Spectrum and Other Psychotic Disorders

Keywords

schizophrenia, psychosis, mHealth, digital health

Brief summary

This protocol describes an attempt to capture the development phase of a mobile support for individuals with schizophrenia. The intent is to describe and account for a rigorous development process that will result in the creation of a beta version that would be tested in a randomized trial for effectiveness - to be addressed in a subsequent protocol

Detailed description

General Issues The most common contributors to relapse in schizophrenia and associated mental illnesses are medication non-adherence, social isolation, and inadequate supports. Driven to a large extent by system of care shortcomings and the many challenges presented by symptoms, the impacts of these problems are profound from individual to system levels. This is a global issue, and to date technology has not been substantively leveraged in generating solutions - despite evidence of substantial uptake of relevant technologies by relevant populations. To date, there are few products on the market that address the constellation of issues outlined above. It is an area where a nuanced approach is needed as this illness is highly diverse in presentation, attended by a number of social determinants of health that greatly affect outcomes and, quite commonly, ambivalence with respect to service provider and caregiver engagement. This scenario as it exists for schizophrenia stands in sharp contrast with the many thousands of applications developed for other mental health issues. Cellphone Based Technologies and Schizophrenia There is a small, emergent literature that is examining the feasibility and outcomes of mobile applications that address schizophrenia. Broadly, targeted mobile and online applications in areas such as cognitive remediation (brain training games) have been found feasible and do not result in any noted risks in their use and there have been promising findings in outcome studies of emergent mHealth strategies for schizophrenia of the kind tested here. Local Work in this Area to Date Initial mapping of key domains relevant to an app in this area has been conducted based upon the experience of the collaborators and an understanding of the relevant practice literatures. This initial draft, which might be considered a 'paper prototype', let to the identification of the following needs: The platform would: * Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement * Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw upon evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises) * Facilitate automated support and link to caregivers * Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness * Provide basic health/safety functionality and track level of wellness Specifically, the app was designed to be made up of 4 functional areas: 1. A needs assessment in order to determine care/interaction pathway, crisis planning and routine builders, accompanied by ongoing assessment to keep components relevant and engaging and to facilitate treatment planning and support by providers. 2. Daily interactions and check-in functionality for self-determination of messaging, reward messaging, social interaction content. 3. An algorithm to determine content based on ambient and interaction data content triggers and risk flagging built on evidence-based guidelines. 4. Self-Management portal and caregiver dashboard. Research Objective This study was undertaken to engage in a rigorous process of feasibility testing. This will then be followed by a randomized trial of the beta version that will be generated through the process outlined in this protocol (will be the subject of a subsequent protocol and not addressed here). As such, the objective of this research is to capture and record the process of development of a functional, beta version of this technology. This test includes outcome data derived from 1 month of app use comprised of both qualitative feedback and quantitative outcome data. The objective is to determine feasibility prior to further trials and validation efforts.

Interventions

COMBINATION_PRODUCTApp4Independence

The mobile, app-based platform was designed to: * Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement * Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw on evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises) * Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness * Provide basic health/safety functionality and track level of wellness * Provide an anonymous peer-peer online network for strategy sharing * Provide an ambient sound detector to assist with identifying hallucinations

Sponsors

Centre for Addiction and Mental Health
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Are 18 years of age or older * Have a schizophrenia spectrum diagnosis * Own and regularly use a smart phone equipped with an Android operating system and a talk and data plan * Read and speak conversational English

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Symptomatology1 MonthThe Brief Symptom Inventory (BSI) assesses the level of psychiatric symptomatology providing both total and subscale scores. All 53 items are 5-point likert with higher scores meaning higher symptomatology. For the overall score the total is used and can range from 0-212. Total scores from each of the 9 subscales are similarly used with higher scores meaning greater subscale symptomatology. Lowest scores for all are 0, with 20 the highest score for hostility, phobic anxiety, paranoid ideation, psychoticism; 16 the highest score for interpersonal sensitivity; 24 the highest for obsessive compulsive, depression, anxiety; and 28 for somatization.
Recovery Process Engagement1 monthPersonal Recovery Outcome Measure (PROM) was used to assess degree of engagement in the recovery process. The prom has 30 items, all 5 point likert with higher scores meaning more recovery engagement. The metric is the total score (0-120)/4 to provide an adjusted score. There are no subscales.
Treatment Adherence1 monthBrief Adherence Rating Scale (BARS) was used to examine implications of A4i for medication use. A total score ranging from 0-100 is provided with 100 indicating better adherence.

Countries

Canada

Participant flow

Participants by arm

ArmCount
Use of mHealth Technology
This single arm of the study involves the provision of the mobile health technology entitled App4Independence. App4Independence: The mobile, app-based platform was designed to: * Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement * Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw on evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises) * Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness * Provide basic health/safety functionality and track level of wellness * Provide an anonymous peer-peer online network for strategy sharing * Provide an ambient sound detector to assist with identifying hallucinations
38
Total38

Baseline characteristics

CharacteristicUse of mHealth Technology
Age, Continuous31.42 years
STANDARD_DEVIATION 8.6
Age of first illness onsent/Age at 1st Hospitalization24.16 years
STANDARD_DEVIATION 7.7
Brief Adherence Rating Scale98.27 units on a scale
STANDARD_DEVIATION 3.1
Brief Symptom Inventory
Anxiety
4.92 units on a scale
STANDARD_DEVIATION 5.5
Brief Symptom Inventory
Depression
6.47 units on a scale
STANDARD_DEVIATION 5.59
Brief Symptom Inventory
Hostility
2.42 units on a scale
STANDARD_DEVIATION 2.41
Brief Symptom Inventory
Interpersonal Sensitivity
4.45 units on a scale
STANDARD_DEVIATION 3.9
Brief Symptom Inventory
OCD
8.21 units on a scale
STANDARD_DEVIATION 5.06
Brief Symptom Inventory
Paranoid Ideation
4.97 units on a scale
STANDARD_DEVIATION 4.54
Brief Symptom Inventory
Phobic Anxiety
3.90 units on a scale
STANDARD_DEVIATION 4.11
Brief Symptom Inventory
Psychoticism
5.34 units on a scale
STANDARD_DEVIATION 4.63
Brief Symptom Inventory
Somatization
4.95 units on a scale
STANDARD_DEVIATION 4.4
Brief Symptom Inventory
Total
46.21 units on a scale
STANDARD_DEVIATION 32.86
Diagnosis
ASD with prominent psychosis symptomatology
1 Participants
Diagnosis
Psychosis NOS or Psychosis comorbid with BPD
1 Participants
Diagnosis
Schizoaffective
9 Participants
Diagnosis
Schizophrenia
24 Participants
Employment
Casual
4 Participants
Employment
Full Time
2 Participants
Employment
Not In Labour Force
6 Participants
Employment
Part Time
6 Participants
Employment
Student
11 Participants
Employment
Unemployed
9 Participants
Level of Education
High School
6 Participants
Level of Education
Junior High/Middle School
4 Participants
Level of Education
Tertiary Education
28 Participants
Living Circumstances
Alone in private dwelling
13 Participants
Living Circumstances
Private dwelling with parents
9 Participants
Living Circumstances
With roomates
9 Participants
Mobile technology use
Daily Use
8 Participants
Mobile technology use
Emailing (1-5 times/day)
21 Participants
Mobile technology use
Hourly Use
30 Participants
Mobile technology use
Social Media (1-5 times/day)
16 Participants
Mobile technology use
Texting (1-5 times/day)
20 Participants
Personal Recovery Outcome Measure7.13 units on a scale
STANDARD_DEVIATION 1.66
Race/Ethnicity, Customized
Black Canadian or African or African Caribbean
9 Participants
Race/Ethnicity, Customized
Mixed
9 Participants
Race/Ethnicity, Customized
Other
4 Participants
Race/Ethnicity, Customized
White
16 Participants
Sex/Gender, Customized
Female
10 Participants
Sex/Gender, Customized
Male
27 Participants
Sex/Gender, Customized
Transgender
1 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 38
other
Total, other adverse events
0 / 38
serious
Total, serious adverse events
0 / 38

Outcome results

Primary

Recovery Process Engagement

Personal Recovery Outcome Measure (PROM) was used to assess degree of engagement in the recovery process. The prom has 30 items, all 5 point likert with higher scores meaning more recovery engagement. The metric is the total score (0-120)/4 to provide an adjusted score. There are no subscales.

Time frame: 1 month

ArmMeasureValue (MEAN)Dispersion
Use of mHealth TechnologyRecovery Process Engagement7.45 score on a scaleStandard Deviation 1.63
p-value: 0.047Paired Sample T-Test
p-value: 0.036Paired Sample T-Test
Primary

Symptomatology

The Brief Symptom Inventory (BSI) assesses the level of psychiatric symptomatology providing both total and subscale scores. All 53 items are 5-point likert with higher scores meaning higher symptomatology. For the overall score the total is used and can range from 0-212. Total scores from each of the 9 subscales are similarly used with higher scores meaning greater subscale symptomatology. Lowest scores for all are 0, with 20 the highest score for hostility, phobic anxiety, paranoid ideation, psychoticism; 16 the highest score for interpersonal sensitivity; 24 the highest for obsessive compulsive, depression, anxiety; and 28 for somatization.

Time frame: 1 Month

ArmMeasureGroupValue (MEAN)Dispersion
Use of mHealth TechnologySymptomatologySomatization4.29 score on a scaleStandard Deviation 5.4
Use of mHealth TechnologySymptomatologyDepression4.29 score on a scaleStandard Deviation 4.57
Use of mHealth TechnologySymptomatologyHostility1.97 score on a scaleStandard Deviation 2.58
Use of mHealth TechnologySymptomatologyPhobic Anxiety2.97 score on a scaleStandard Deviation 3.75
Use of mHealth TechnologySymptomatologyOCD6.37 score on a scaleStandard Deviation 4.7
Use of mHealth TechnologySymptomatologyAnxiety4.63 score on a scaleStandard Deviation 4.81
Use of mHealth TechnologySymptomatologyParanoid Ideation3.71 score on a scaleStandard Deviation 3.49
Use of mHealth TechnologySymptomatologyInterpersonal Sensitivity3.74 score on a scaleStandard Deviation 3.94
Use of mHealth TechnologySymptomatologyTotal41.66 score on a scaleStandard Deviation 33.8
Use of mHealth TechnologySymptomatologyPsychoticism4.34 score on a scaleStandard Deviation 4.23
p-value: 0.067Paired Sample T-Test
p-value: 0.071Paired Sample T-Test
Primary

Treatment Adherence

Brief Adherence Rating Scale (BARS) was used to examine implications of A4i for medication use. A total score ranging from 0-100 is provided with 100 indicating better adherence.

Time frame: 1 month

ArmMeasureValue (MEAN)Dispersion
Use of mHealth TechnologyTreatment Adherence98.94 score on a scaleStandard Deviation 2.35
p-value: 0.032Paired Sample T-Test
p-value: 0.006Paired Sample T-Test

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026